What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
48
PTGX Quote, Financials, Valuation and Earnings
Last price:
$43.47
Seasonality move
:
34.62%
Day range:
$43.27 - $45.23
52-week range:
$27.00 - $60.60
Dividend yield:
0%
P/E ratio:
59.03x
P/S ratio:
13.45x
P/B ratio:
3.98x
Volume:
910.1K
Avg. volume:
1.2M
1-year change:
50.99%
Market cap:
$2.7B
Revenue:
$434.4M
EPS (TTM):
$0.75
Protagonist Therapeutics SEC Filings
| Company | Filed | Form Type | Description | |
|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics
|
11/02/2023 | 10-Q | 10-Q filing on 11/02/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/03/2023 | 10-Q | 10-Q filing on 08/03/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2023 | 10-Q | 10-Q filing on 05/04/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/08/2022 | 10-Q | 10-Q filing on 11/08/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2022 | 10-Q | 10-Q filing on 08/04/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/05/2022 | 10-Q | 10-Q filing on 05/05/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/03/2021 | 10-Q | 10-Q filing on 11/03/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2021 | 10-Q | 10-Q filing on 08/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2021 | 10-Q | 10-Q filing on 05/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/04/2020 | 10-Q | 10-Q filing on 11/04/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/06/2020 | 10-Q | 10-Q filing on 08/06/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/07/2020 | 10-Q | 10-Q filing on 05/07/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/10/2020 | 10-K | 10-K filing on 03/10/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2019 | 10-Q | 10-Q filing on 11/06/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2019 | 10-Q | 10-Q filing on 08/07/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/08/2019 | 10-Q | 10-Q filing on 05/08/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/12/2019 | 10-K | 10-K filing on 03/12/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2018 | 10-Q | 10-Q filing on 11/06/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2018 | 10-Q | 10-Q filing on 08/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/09/2018 | 10-Q | 10-Q filing on 05/09/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2018 | 10-K | 10-K filing on 03/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/07/2017 | 10-Q | 10-Q filing on 11/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/08/2017 | 10-Q | 10-Q filing on 08/08/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/10/2017 | 10-Q | 10-Q filing on 05/10/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2017 | 10-K | 10-K filing on 03/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/14/2016 | 10-Q | 10-Q filing on 11/14/2016 | View Form |
|
PTGX
Protagonist Therapeutics
|
09/15/2016 | 10-Q | 10-Q filing on 09/15/2016 | View Form |
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is up 8.9% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 4.72% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 2.36% over the past day.
